CRISPR Therapeutics AG (CRSP) Dividend History

Company News

• CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

  CRISPR Therapeutics announced positive Phase 1 clinical data for CTX310, a gene therapy targeting ANGPTL3, showing significant reductions in triglycerides and LDL cholesterol with a well-tolerated safety profile. The company is advancing multiple cardiovascular disease programs and expects to present complete data in late 2025.

  GlobeNewswire Inc.

  Featured Companies: VRTX
• The Best Stocks to Invest $1,000 in Right Now

  The article discusses three stocks that are good investment options right now: Shopify, CRISPR Therapeutics, and Confluent. Shopify is seen as a positive investment due to its growth potential in the e-commerce space, CRISPR Therapeutics is seen as a positive investment due to its promising CRISPR technology, and Confluent is seen as a positive investment due to its data streaming solutions.

  The Motley Fool

  Featured Companies: CFLT SHOP
• CRISPR Therapeutics Stock Near 5-Year Lows—But Gene Editing’s Future Is Just Begin

  CRISPR Therapeutics (CRSP) stock is trading near 5-year lows, but the company's gene editing treatment CASGEVY for sickle cell disease and beta-thalassemia has been approved in multiple jurisdictions. The company's future growth potential in gene editing is promising, but the high cost of CASGEVY may be a challenge.

  Investing.com
• The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna

  Vertex Pharmaceuticals reported a wider-than-expected Q2 loss due to costs related to the acquisition of Alpine Immune Sciences. However, the company's strong fundamentals, including its dominant position in the cystic fibrosis market and a robust pipeline, make it a good long-term investment despite the recent stock price dip.

  Zacks Investment Research
• Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

  CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia. Read why I've upgraded CRSP stock from Sell to Hold.

  Seeking Alpha

  Featured Companies: BLUE VRTX